Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in Proc Natl Acad Sci U S A

Retrieve available abstracts of 55 articles:
HTML format



Single Articles


    August 2022
  1. WANG Z, Zhu J, Liu Y, Wang Z, et al
    Tumor-polarized GPX3(+) AT2 lung epithelial cells promote premetastatic niche formation.
    Proc Natl Acad Sci U S A. 2022;119:e2201899119.
    PubMed     Abstract available


    July 2022
  2. BROWN BP, Zhang YK, Kim S, Finneran P, et al
    Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2206588119.
    PubMed     Abstract available


  3. WANG D, Wang Q, Wang Y, Chen P, et al
    Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides.
    Proc Natl Acad Sci U S A. 2022;119:e2113180119.
    PubMed     Abstract available


  4. MA L, Yang F, Wu X, Mao C, et al
    Structural basis and molecular mechanism of biased GPBAR signaling in regulating NSCLC cell growth via YAP activity.
    Proc Natl Acad Sci U S A. 2022;119:e2117054119.
    PubMed     Abstract available


    May 2022

  5. Retraction for Motiwala et al., Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2200127119.
    PubMed    


  6. SCHOLZ A, DeFalco J, Leung Y, Aydin IT, et al
    Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101.
    Proc Natl Acad Sci U S A. 2022;119:e2123483119.
    PubMed     Abstract available


  7. FENG S, Callow MG, Fortin JP, Khan Z, et al
    A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS(G12C) inhibitors.
    Proc Natl Acad Sci U S A. 2022;119:e2120512119.
    PubMed     Abstract available


    April 2022
  8. AHMED M, Kaur N, Cheng Q, Shanabrough M, et al
    A hypothalamic pathway for Augmentor alpha-controlled body weight regulation.
    Proc Natl Acad Sci U S A. 2022;119:e2200476119.
    PubMed     Abstract available


    February 2022
  9. XU Q, Wang C, Zhou JX, Xu ZM, et al
    Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  10. SONG NY, Li X, Ma B, Willette-Brown J, et al
    IKKalpha-deficient lung adenocarcinomas generate an immunosuppressive microenvironment by overproducing Treg-inducing cytokines.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


    December 2021
  11. SCHULT TA, Lauer MJ, Berker Y, Cardoso MR, et al
    Screening human lung cancer with predictive models of serum magnetic resonance spectroscopy metabolomics.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  12. ZHAO X, Hu J, Li Y, Guo M, et al
    Volumetric compression develops noise-driven single-cell heterogeneity.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    November 2021
  13. CHEON H, Holvey-Bates EG, McGrail DJ, Stark GR, et al
    PD-L1 sustains chronic, cancer cell-intrinsic responses to type I interferon, enhancing resistance to DNA damage.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  14. DE S, Holvey-Bates EG, Mahen K, Willard B, et al
    The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    September 2021
  15. LLABATA P, Torres-Diz M, Gomez A, Tomas-Daza L, et al
    MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available



  16. Correction for Jeon et al., A set of NF-kappaB-regulated microRNAs induces acquired TRAIL resistance in Lung cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed    


    August 2021
  17. MUELLER HS, Fowler CE, Dalin S, Moiso E, et al
    Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    July 2021
  18. SALMON M, Paniagua G, Lechuga CG, Fernandez-Garcia F, et al
    KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  19. LIU Z, Wang F, Liu X, Sang Y, et al
    Cell membrane-camouflaged liposomes for tumor cell-selective glycans engineering and imaging in vivo.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    June 2021
  20. ETXEBERRIA I, Bolanos E, Teijeira A, Garasa S, et al
    Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  21. SHI L, Tan X, Liu X, Yu J, et al
    Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3-amplified lung adenocarcinoma cells.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  22. SANCHEZ-RIVERA FJ, Ryan J, Soto-Feliciano YM, Clare Beytagh M, et al
    Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    May 2021
  23. PRADHAN AK, Maji S, Bhoopathi P, Talukdar S, et al
    Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1beta.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  24. DING Y, Liu Y, Lee DK, Tong Z, et al
    Cell lineage tracing links ERalpha loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  25. TIEN JC, Chugh S, Goodrum AE, Cheng Y, et al
    AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  26. WANG R, Godet I, Yang Y, Salman S, et al
    Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  27. TILSTON-LUNEL A, Mazzilli S, Kingston NM, Szymaniak AD, et al
    Aberrant epithelial polarity cues drive the development of precancerous airway lesions.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    April 2021
  28. WAN PK, Tong KC, Lok CN, Zhang C, et al
    Platinum(II) N-heterocyclic carbene complexes arrest metastatic tumor growth.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    March 2021
  29. YANG L, Yan X, Chen J, Zhan Q, et al
    Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  30. BROWNLIE D, Scharenberg M, Mold JE, Hard J, et al
    Expansions of adaptive-like NK cells with a tissue-resident phenotype in human lung and blood.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    February 2021
  31. JIMENEZ-SANCHEZ J, Bosque JJ, Jimenez Londono GA, Molina-Garcia D, et al
    Evolutionary dynamics at the tumor edge reveal metabolic imaging biomarkers.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    January 2021
  32. CHIBAYA L, Karim B, Zhang H, Jones SN, et al
    Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  33. XIAO Y, Lin FT, Lin WC
    ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    December 2020
  34. HOJ JP, Mayro B, Pendergast AM
    The ABL2 kinase regulates an HSF1-dependent transcriptional program required for lung adenocarcinoma brain metastasis.
    Proc Natl Acad Sci U S A. 2020 Dec 14. pii: 2007991117.
    PubMed     Abstract available


  35. MAYRHOFER JE, Enzler F, Feichtner A, Rock R, et al
    Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies.
    Proc Natl Acad Sci U S A. 2020;117:31105-31113.
    PubMed     Abstract available


    November 2020
  36. VASSEL FM, Bian K, Walker GC, Hemann MT, et al
    Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer.
    Proc Natl Acad Sci U S A. 2020 Nov 3. pii: 2016067117.
    PubMed     Abstract available


    September 2020
  37. ESTEBAN-BURGOS L, Wang H, Nieto P, Zheng J, et al
    Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
    Proc Natl Acad Sci U S A. 2020;117:24415-24426.
    PubMed     Abstract available


  38. YING L, Du L, Zou R, Shi L, et al
    Development of a serum miRNA panel for detection of early stage non-small cell lung cancer.
    Proc Natl Acad Sci U S A. 2020 Sep 17. pii: 2006212117.
    PubMed     Abstract available


    August 2020
  39. LIU C, Xu X, Han L, Wan X, et al
    LRCH1 deficiency enhances LAT signalosome formation and CD8(+) T cell responses against tumors and pathogens.
    Proc Natl Acad Sci U S A. 2020;117:19388-19398.
    PubMed     Abstract available


    July 2020
  40. SMITH HW, Yang L, Ling C, Walsh A, et al
    An ErbB2 splice variant lacking exon 16 drives lung carcinoma.
    Proc Natl Acad Sci U S A. 2020 Jul 29. pii: 2007474117.
    PubMed     Abstract available


    March 2020
  41. WANG X, Yang X, Zhang C, Wang Y, et al
    Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.
    Proc Natl Acad Sci U S A. 2020;117:6640-6650.
    PubMed     Abstract available


  42. NA TY, Schecterson L, Mendonsa AM, Gumbiner BM, et al
    The functional activity of E-cadherin controls tumor cell metastasis at multiple steps.
    Proc Natl Acad Sci U S A. 2020;117:5931-5937.
    PubMed     Abstract available


  43. PHILLIPS JW, Pan Y, Tsai BL, Xie Z, et al
    Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers.
    Proc Natl Acad Sci U S A. 2020;117:5269-5279.
    PubMed     Abstract available


  44. TANG MS
    Reply to Young and Scott: Nicotine and nicotinic acetylcholine receptor mutations in electronic-cigarette smoke lung carcinogenicity.
    Proc Natl Acad Sci U S A. 2020;117:4462-4463.
    PubMed    


  45. JIANG H, Cao HJ, Ma N, Bao WD, et al
    Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis.
    Proc Natl Acad Sci U S A. 2020;117:4770-4780.
    PubMed     Abstract available


  46. KESAVAN R, Fromel T, Zukunft S, Laban H, et al
    Cyp2c44 regulates prostaglandin synthesis, lymphangiogenesis, and metastasis in a mouse model of breast cancer.
    Proc Natl Acad Sci U S A. 2020 Mar 2. pii: 1921381117.
    PubMed     Abstract available


    February 2020
  47. BRANDT AC, McNally L, Lorimer EL, Unger B, et al
    Splice switching an oncogenic ratio of SmgGDS isoforms as a strategy to diminish malignancy.
    Proc Natl Acad Sci U S A. 2020;117:3627-3636.
    PubMed     Abstract available


  48. VITOS-FALEATO J, Real SM, Gutierrez-Prat N, Villanueva A, et al
    Requirement for epithelial p38alpha in KRAS-driven lung tumor progression.
    Proc Natl Acad Sci U S A. 2020;117:2588-2596.
    PubMed     Abstract available


    January 2020
  49. NAIR P
    QnAs with Sangeeta N. Bhatia.
    Proc Natl Acad Sci U S A. 2020;117:1243-1245.
    PubMed    


  50. NEWMAN JH, Chesson CB, Herzog NL, Bommareddy PK, et al
    Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer.
    Proc Natl Acad Sci U S A. 2020;117:1119-1128.
    PubMed     Abstract available


  51. WINKLER I, Bitter C, Winkler S, Weichenhan D, et al
    Identification of Ppargamma-modulated miRNA hubs that target the fibrotic tumor microenvironment.
    Proc Natl Acad Sci U S A. 2020;117:454-463.
    PubMed     Abstract available


    November 2019
  52. LINETTE GP, Becker-Hapak M, Skidmore ZL, Baroja ML, et al
    Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Proc Natl Acad Sci U S A. 2019 Nov 4. pii: 1906026116.
    PubMed     Abstract available


    September 2019
  53. YIN Y, Xie CM, Li H, Tan M, et al
    The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.
    Proc Natl Acad Sci U S A. 2019 Sep 23. pii: 1905973116.
    PubMed     Abstract available


  54. LIM SB, Yeo T, Lee WD, Bhagat AAS, et al
    Addressing cellular heterogeneity in tumor and circulation for refined prognostication.
    Proc Natl Acad Sci U S A. 2019;116:17957-17962.
    PubMed     Abstract available


    August 2019
  55. SCHMIDT L, Eskiocak B, Kohn R, Dang C, et al
    Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation.
    Proc Natl Acad Sci U S A. 2019;116:17460-17469.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: